Handelsbanken Fonder AB Buys 36,697 Shares of Moderna, Inc. (NASDAQ:MRNA)

Handelsbanken Fonder AB boosted its stake in Moderna, Inc. (NASDAQ:MRNA) by 30.5% in the 4th quarter, Holdings Channel reports. The firm owned 156,970 shares of the company’s stock after acquiring an additional 36,697 shares during the quarter. Handelsbanken Fonder AB’s holdings in Moderna were worth $6,527,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in MRNA. Blue Trust Inc. boosted its stake in Moderna by 365.6% in the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after purchasing an additional 574 shares during the period. Raymond James & Associates boosted its position in shares of Moderna by 19.7% during the 3rd quarter. Raymond James & Associates now owns 162,074 shares of the company’s stock valued at $10,831,000 after acquiring an additional 26,657 shares during the last quarter. International Assets Investment Management LLC boosted its position in shares of Moderna by 10,687.1% during the 3rd quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock valued at $21,353,000 after acquiring an additional 316,552 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in shares of Moderna by 79.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 13,159 shares of the company’s stock valued at $879,000 after acquiring an additional 5,807 shares during the last quarter. Finally, E. Ohman J or Asset Management AB bought a new stake in shares of Moderna during the 3rd quarter valued at about $942,000. Institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

Shares of Moderna stock opened at $35.53 on Friday. The business’s 50 day simple moving average is $38.04 and its two-hundred day simple moving average is $52.66. The stock has a market capitalization of $13.67 billion, a P/E ratio of -3.83 and a beta of 1.59. Moderna, Inc. has a one year low of $29.25 and a one year high of $170.47.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 2,664 shares of company stock valued at $115,210 in the last ninety days. Company insiders own 15.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on MRNA shares. Bank of America dropped their price target on Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research report on Tuesday, February 11th. HSBC upgraded Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target for the company in a research report on Monday, November 18th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Friday, November 8th. JPMorgan Chase & Co. set a $45.00 price target on Moderna in a research report on Friday, February 14th. Finally, Morgan Stanley dropped their price target on Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 15th. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Moderna has a consensus rating of “Hold” and an average target price of $60.63.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.